Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06275126
Other study ID # 23-08026433
Secondary ID R01CA256877-01A1
Status Recruiting
Phase N/A
First received
Last updated
Start date March 13, 2024
Est. completion date May 2027

Study information

Verified date April 2024
Source Weill Medical College of Cornell University
Contact Shoshana Rosenberg, ScD, MPH
Phone 646-962-8041
Email shr4009@med.cornell.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this study is to understand and improve the breast surgical decision-making process for young women newly diagnosed with breast cancer. As part of this study, the investigators will evaluate the impact and use a web-based tool called CONSYDER that is designed to provide useful information to young breast cancer patients. It is also meant to improve communication between young women and their surgeons with the purpose of helping patients make appropriate surgical decisions. Participants will complete surveys within 1 week of the surgical consult and 6 months after surgery. Patients who receive neoadjuvant chemotherapy will also be surveyed after the completion of neoadjuvant treatment but prior to surgery. Some patients will be invited for an interview after their surgery as part of the evaluation. A subset of patients/surgeons will also have their surgical consultation audio-recorded.


Description:

Primary objectives: - To test the effectiveness of the CONSYDER decision support tool on reducing decisional conflict prior to breast cancer surgery. - To evaluate the implementation of and mechanisms of use for CONSYDER. Secondary Objectives: - To determine the impact of CONSYDER on decision-making preferences, breast cancer knowledge, treatment goals and preferences, anxiety, decisional regret, and self-efficacy in communication. Exploratory Objectives: - To explore whether CONSYDER impacts surgical choice. OUTLINE: This is a multi-site cluster randomized trial using a stepped wedge design. Approximately 800 women will be recruited at 4 study sites (Weill Cornell Medicine, Yale Cancer Center, Dana-Farber Cancer Institute, Duke Cancer Institute), including network affiliate sites, over an approximate 30-month period. All sites will have a 6-month "run-in" period where patients will not be sent CONSYDER. The 6-month blocks may be extended if recruitment targets are not met. Sites will be randomized to begin delivery of CONSYDER to all newly diagnosed women, age ≤44, with Stage 0-III breast cancer as part of routine clinical care; young women will have access to the website whether or not they consent to research study participation.


Recruitment information / eligibility

Status Recruiting
Enrollment 800
Est. completion date May 2027
Est. primary completion date September 2026
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 44 Years
Eligibility Inclusion Criteria: - Female aged 18-44 - New diagnosis of Stage 0, 1, 2, or 3 unilateral breast cancer - English or Spanish speaking Exclusion Criteria: - Diagnosis of de novo Stage 4 breast cancer - Recurrent early-stage breast cancer - Bilateral breast cancer

Study Design


Intervention

Other:
CONSYDER decision aid
Web-based breast cancer surgery decision aid

Locations

Country Name City State
United States Dana-Farber Cancer Institute Boston Massachusetts
United States Duke Cancer Institute Durham North Carolina
United States Yale Cancer Center New Haven Connecticut
United States Weill Cornell Medicine New York New York

Sponsors (3)

Lead Sponsor Collaborator
Weill Medical College of Cornell University National Cancer Institute (NCI), National Institutes of Health (NIH)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Pre-surgical decisional conflict as measured by the Decisional Conflict Scale (DCS) The Decisional Conflict Scale (DCS) includes 5 subscales (uncertainty, informed, values clarity, support, effective decision). Each item is rated on a scale of 0 (strongly agree)-4 (strongly disagree). Scores range from 0-100 with higher scores indicating more decisional conflict. pre-surgery
Primary Use of CONSYDER pre-consult Proportion of patients eligible to use CONSYDER who logged in prior to surgical consult pre-surgery
Secondary Knowledge as measured by adapted Breast Cancer Surgery Decision Quality Instrument (BCS -DQI) Breast cancer knowledge will be assessed using selected questions from the adapted Breast Cancer Surgery Decision Quality Instrument (BCS -DQI), an instrument designed to evaluate the quality of breast cancer treatment decisions. The number of correct responses across (out of a total of 5 items) will be summed. pre-surgery
Secondary Treatment goals and preferences as measured by adapted Breast Cancer Surgery Decision Quality Instrument (BCS-DQI) Treatment goals and preferences have been adapted from the BCS-DQI to include preferences salient to young women. We will ask participants to mark on a scale (not important, 0-extremely important, 10) the importance of several reasons in relation to their surgical decision. Ratings for each item will be summarized (e.g., mean, median, range). pre-surgery
Secondary Anxiety, as measured with the 8-item Patient Reported Outcomes Measurement Information System (PROMIS) - Anxiety - Short Form Anxiety, as measured with the 8-item PROMIS - Anxiety - Short Form. Response options for each item range from never (1) to always (5). Raw scores range from 5-40 and T-scores range from 37.1-83.1. Higher scores indicate higher levels of anxiety. pre-surgery and 6 months post-surgery
Secondary Self-efficacy in communication as measured by the Perceived Efficacy in Patient-Physician Interactions scale (PEPPI). Perceived Efficacy in Patient-Physician Interactions scale (PEPPI) has 5 items. Each item is rated on a (0, not confident at all - 10, extremely confident) scale. Scores range from 0-50, with higher scores indicating greater self-efficacy. pre-surgery
Secondary Decisional regret as measured by the Decision Regret Scale (DRS) The Decision Regret Scale (DRS) includes 5 items. Each item is rated on a scale of 1 (strongly agree)-5 (strongly disagree). Scores range from 0-100 (item scores are converted by subtracting "1" from individual items and multiplying by 25). Higher scores indicate more decisional regret. 6 months post-surgery
Secondary Receipt of contralateral prophylactic mastectomy Proportion of patients who undergo contralateral prophylactic mastectomy 6 months post-surgery
Secondary Fidelity of implementation of CONSYDER via patient portal email Proportion of patients eligible to use CONSYDER who were sent an email from patient portal pre-surgical consult
Secondary Use of CONSYDER post-consult Proportion of patients who logged in to CONSYDER post-surgical consult up to 6 months post-surgical consult
Secondary Frequency of CONSYDER use pre-consult Count of the number log-ins to CONSYDER pre-consult pre consult
Secondary Frequency of CONSYDER use post-consult Count of the number log-ins to CONSYDER post-consult up to 6 months post-surgical consult
See also
  Status Clinical Trial Phase
Recruiting NCT05528263 - Preventing Chemotherapy-Induced Peripheral Neuropathy With Acupuncture (PACT Trial) N/A
Recruiting NCT03270072 - The Differential Impact of Proton Beam Irradiation Versus Conventional Radiation on Organs-at-risk in Stage II-III Breast Cancer Patients
Terminated NCT03723863 - Occupational Therapist-Led Work Intervention in Facilitating Work Maintenance or Re-entry to the Workforce in Patients With Stage I to III Breast Cancer Undergoing Chemotherapy N/A
Completed NCT00393341 - Quantitation of Endothelial Progenitor Cells as Markers of Tumor Angiogenesis in Breast Cancer N/A
Recruiting NCT05558722 - Anlotinib Combined With Chemotherapy and Neoadjuvant Therapy for Hormone Receptor-positive HER-2 Negative Breast Cancer Phase 2
Active, not recruiting NCT04180579 - Safety of Lower Scalp Cooling Temperature to Prevent Hair Loss From Chemotherapy in Breast Cancer Patients N/A
Recruiting NCT03879577 - Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer Phase 2
Withdrawn NCT03058939 - Assessing the Response Rate of Neo-adjuvant Paclitaxel (Taxol) in Nigerian Women With Breast Cancer Phase 2
Recruiting NCT05877859 - Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant Chemo-immunotherapy With Pembrolizumab
Recruiting NCT05296746 - Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer Phase 2
Withdrawn NCT05774886 - Implantable Microdevice for TNBC - Pilot Study Phase 1
Completed NCT01599039 - Study the Usefulness of Bio-impedance Spectroscopy in the Early Assessment of Breast Cancer Related Lymphoedema N/A
Unknown status NCT01352494 - Neoadjuvant Chemotherapy With Docetaxel and Gemcitabine in Locally Advanced Breast Cancer Phase 2
Completed NCT03578627 - Stress and Immunity Breast Cancer Project N/A
Not yet recruiting NCT05724758 - Patient Reported Outcomes After Oncoplastic Breast Conserving Surgery
Active, not recruiting NCT03766009 - Increasing Patients' Engagement in Breast Cancer Surgery Decision-Making N/A
Recruiting NCT05406531 - The Effectiveness of Psychological Interventions in Psycho-neuroendocrine-immune Network in Breast Cancer Survivors N/A
Active, not recruiting NCT03609047 - Adjuvant Palbociclib in Elderly Patients With Breast Cancer Phase 2
Recruiting NCT05898789 - Virtual Rehabilitation for Cancer Survivors N/A
Recruiting NCT06006806 - Evaluation of Radiobiological Effects in Skin Toxicities for Breast Cancer Patients With Pencil Beam Scanning Proton Therapy N/A